# Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

> **NCT04373083** · PHASE2 · WITHDRAWN · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Cemiplimab
- **RADIATION:** Involved-site radiotherapy (IS-RT)

## Key facts

- **NCT ID:** NCT04373083
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-15
- **Primary completion:** 2022-12-20
- **Final completion:** 2025-02-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2021-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373083, "Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04373083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*